1616760-97-4 Usage
Description
Tofacitinib Impurity 2, also known as 3,4-dimethylisothiazole, is a chemical compound that serves as an impurity in the production of the drug tofacitinib. It is an intermediate in the synthesis of tofacitinib and plays a crucial role in the manufacturing process. Due to its potential impact on the safety and effectiveness of the medication, strict regulations and quality control measures are implemented to ensure that only trace amounts of this impurity are present in the final drug formulation.
Uses
Used in Pharmaceutical Industry:
Tofacitinib Impurity 2 is used as a quality control parameter for ensuring the purity and quality of the final drug product, tofacitinib. It is monitored and controlled during the manufacturing process to minimize its presence in the final formulation, thereby maintaining the safety and effectiveness of the medication.
Tofacitinib Impurity 2 is used as a regulatory compliance indicator for adhering to strict regulations and quality control measures in the pharmaceutical industry. By ensuring that only trace amounts of this impurity are present in the final drug formulation, manufacturers can comply with industry standards and regulatory requirements, ultimately safeguarding patient health and well-being.
Check Digit Verification of cas no
The CAS Registry Mumber 1616760-97-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,1,6,7,6 and 0 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1616760-97:
(9*1)+(8*6)+(7*1)+(6*6)+(5*7)+(4*6)+(3*0)+(2*9)+(1*7)=184
184 % 10 = 4
So 1616760-97-4 is a valid CAS Registry Number.
1616760-97-4Relevant articles and documents
Tropsch process for cloth intermediate impurity, tofa for cloth impurity and its synthesis method, and Tropsch process for the cloth quality monitoring method
-
Paragraph 0044-0046; 0049; 0052; 0054, (2017/08/26)
The invention provides a tofacitinib intermediate impurity, tofacitinib impurity and a synthetic method, and a tofacitinib quality monitoring method. The tofacitinib intermediate impurity has a chemical formula in a formula (I), and the tofacitinib impurity has a chemical formula in a formula (II). Through the provided tofacitinib intermediate impurity and the tofacitinib impurity, the invention provides a standard contrast product for monitoring and optimizing quality of N-methyl-N-((3R,4R)-4-methyl piperidine-3-group)-7H-pyrrolo[2,3-D]pyrimidine-4-amine (tofacitinib), and then performs qualitative and quantitative analysis on the tofacitinib intermediate and tofacitinib.
